D. E. Shaw & Co., Inc. Iovance Biotherapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 30,812 shares of IOVA stock, worth $120,166. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,812
Previous 67,748
54.52%
Holding current value
$120,166
Previous $636,000
64.15%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding IOVA
# of Institutions
343Shares Held
247MCall Options Held
2.51MPut Options Held
3.5M-
Vanguard Group Inc Valley Forge, PA27.5MShares$107 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$95.2 Million24.02% of portfolio
-
Perceptive Advisors LLC New York, NY22.1MShares$86.2 Million5.46% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$82.8 Million0.0% of portfolio
-
State Street Corp Boston, MA12.2MShares$47.8 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $615M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...